Can a drug go back on the shortage list?

Yes. FDA adds and removes drugs based on manufacturer reports and its own assessment; a renewed shortage would reopen the shortage-based basis for compounding.

Published August 27, 2026 · updated August 27, 2026 · regulatory and clinical facts last checked 2026-08-27 · medically reviewed by Dr. S. Shuwart, MD on August 27, 2026

Medically reviewed · August 27, 2026

What happens to compounded GLP-1s when an FDA shortage ends

The mechanism that allowed compounded copies of tirzepatide and semaglutide during the shortages, what changes when FDA declares a shortage resolved, the wind-down periods, and what patients on compounded plans should expect.

The mechanism

Federal law restricts compounding a drug that is essentially a copy of a commercially available approved product. FDA’s guidance for both 503A pharmacies and 503B outsourcing facilities treats a drug that appears on FDA’s drug shortage list as not commercially available for this purpose, so while tirzepatide and semaglutide were in shortage, compounders could make copies and telehealth providers could sell them. That is how compounded GLP-1s became a national market.

What changes at resolution

When FDA determines that supply meets or exceeds demand, it moves the drug to “resolved” and the shortage basis ends. FDA has in both GLP-1 cases announced periods during which it would not take enforcement action against compounders for the copy restriction alone, to allow wind-down: for tirzepatide, until 18 February 2025 for 503A and 19 March 2025 for 503B; for semaglutide, until 22 April 2025 for 503A and 22 May 2025 for 503B. After those dates the ordinary rules applied.

What remains possible after resolution

Compounding that is not a copy: a prescriber-documented change that produces a significant difference for the patient (503A), or a presentation not commercially available. FDA has signalled that it examines whether variations are genuine or are used to circumvent the restriction. The personalised compounding page covers this.

What patients on compounded plans should expect

Providers may change formulations, switch pharmacies, move to approved products, or stop. Prepaid multi-month plans carry the risk that a change arrives before the plan ends; the cancellation-terms analysis records what each provider says about refunds in that case. Month-to-month and per-order plans limit the exposure, which is one reason commitment flexibility is a scored factor on this site.

Questions this page answers

Can a drug go back on the shortage list?: Yes. FDA adds and removes drugs based on manufacturer reports and its own assessment; a renewed shortage would reopen the shortage-based basis for compounding.

Sources

FDA Drug Shortages database (regulator)
FDA guidance: Compounded drug products that are essentially copies of a commercially available drug product under section 503A (regulator)
FDA guidance: Compounded drug products that are essentially copies of approved drug products under section 503B (regulator)

Educational information, not medical advice. Decisions about GLP-1 medication belong with you and a licensed clinician who knows your history. Compounded medications are not FDA-approved. Report an error.